The detection power for limited number of early stage patients (n = 22) was also higher than existing biomarker CEA (Figure 5c and 5d), but so far we can conclude that the exosomal CD91 assay could detect at least a large cancer burden. This evidence concerns the gene LRP1 and cancer.